Biogen outlines a gloomy forecast due to generics, Aduhelm controversy

Battered by headwinds tied to its hotly contested Alzheimer’s drug, as well as competition from biosimilars and generics, Biogen Inc. saw an 18% year-over-year revenue drop in 2021, and it expects to make only about $10 billion in revenue this year.